Zafgen reports second death in key drug study
Zafgen Inc. on Wednesday reported a second patient death in an ongoing study of its potential treatment for a rare genetic disorder linked to obesity.
Dec 2, 2015
0
0
Zafgen Inc. on Wednesday reported a second patient death in an ongoing study of its potential treatment for a rare genetic disorder linked to obesity.
Dec 2, 2015
0
0
(HealthDay)—Coagadex (coagulation Factor X) has been approved by the U.S. Food and Drug Administration as the first coagulation factor replacement therapy for people with a rare blood disorder known as hereditary Factor ...
Oct 21, 2015
0
3
(HealthDay)—Patients who take the heart rhythm drug digoxin may face a nearly 30 percent greater risk of death than patients not taking the drug, a review of prior research suggests.
Mar 4, 2015
0
73
(HealthDay)—A new anti-clotting drug to reduce the risk of dangerous blood clots and strokes in people with a type of heart rhythm disorder has been approved by the U.S. Food and Drug Administration.
Jan 9, 2015
0
35
A new class of synthetic platelet-like particles could augment natural blood clotting for the emergency treatment of traumatic injuries – and potentially offer doctors a new option for curbing surgical bleeding and addressing ...
Sep 7, 2014
0
0
(Medical Xpress)—A new test for blood cancers will catch many more cases than the present test that identifies only 60 per cent.
Dec 11, 2013
0
0
One of regenerative medicine's greatest goals is to develop new treatments for stroke. So far, stem cell research for the disease has focused on developing therapeutic neurons—the primary movers of electrical impulses in ...
Jul 23, 2013
0
0
An Australian researcher has found the third and final missing piece in the genetic puzzle of an unusual form of hemophilia, more than 20 year after he discovered the first two pieces.
Mar 7, 2013
0
0
(Medical Xpress)—Australians are being warned of a higher risk of stroke caused by the nation's most common heart rhythm disorder, atrial fibrillation.
Feb 11, 2013
0
0
(HealthDay)—Pomalyst (pomalidomide) has been approved by the U.S. Food and Drug Administration to treat cases of multiple myeloma that have not responded to other therapies.
Feb 9, 2013
0
0